[Skip to Navigation]
March 25, 2020

Treatment of PD-1/PD-L1 Inhibitor–Induced Dermatitis Resolves Concomitant Eruptive Keratoacanthomas

Author Affiliations
  • 1Department of Dermatology, University of California, San Francisco
  • 2Department of Pathology and Laboratory Medicine, University of Colorado School of Medicine, Aurora
  • 3Helen Diller Cancer Center, Department of Pathology and Dermatology, University of California, San Francisco
JAMA Dermatol. 2020;156(5):598-600. doi:10.1001/jamadermatol.2020.0176

Patients who develop eruptive keratoacanthomas (KAs) in the setting of PD-1/PD-L1 inhibitor–induced dermatitis are challenging to treat and discontinue immunotherapy at a much higher rate than those without KAs.1-4 We successfully used 3 different nonsurgical anti-inflammatory therapies to treat both immunotherapy-induced dermatitis and concomitant eruptive KAs.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words